NexgenRx (NXG) Stock Statistics & Valuation Metrics
Total Valuation
NexgenRx has a market cap or net worth of CAD 51.92M. The enterprise value is -CAD 830.36K.
- Market Cap
- CAD 51.92M
- Enterprise Value
- -CAD 830.36K
Share Statistics
NexgenRx has 71,117,134 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 71,117,134
- Owned by Insiders
- 0.01%
- Owned by Institutions
- ―
Financial Efficiency
NexgenRx’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- 29.39K
- Employee Count
- 20
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, NexgenRx had revenue of ― and earned 587.80K in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- 4.64M
- Operating Income
- 516.91K
- Pretax Income
- ―
- Net Income
- 587.80K
- EBITDA
- 511.85K
- Earnings Per Share (EPS)
- ―
Dividends & Yields
NexgenRx pays an annual dividend of ―, resulting in a dividend yield of 2.74%
- Dividend Per Share
- ―
- Dividend Yield
- 2.74%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- ―
- Earnings Yield
- ―
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- 92.11%
- 50-Day Moving Average
- 0.63
- 200-Day Moving Average
- 0.47
- Relative Strength Index (RSI)
- 62.08
- Average Volume (3m)
- 24.49K
Important Dates
NexgenRx upcoming earnings date is Nov 19, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 20, 2026
- Next Earnings Date
- Nov 19, 2026
- Ex-Dividend Date
- ―
Balance Sheet
NexgenRx has ― in cash and marketable securities with CAD 1.75M in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 1.75M
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for NexgenRx is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 17.36%
- EPS Growth Forecast
- 220.19%
